JP2022513700A5 - - Google Patents

Info

Publication number
JP2022513700A5
JP2022513700A5 JP2021531492A JP2021531492A JP2022513700A5 JP 2022513700 A5 JP2022513700 A5 JP 2022513700A5 JP 2021531492 A JP2021531492 A JP 2021531492A JP 2021531492 A JP2021531492 A JP 2021531492A JP 2022513700 A5 JP2022513700 A5 JP 2022513700A5
Authority
JP
Japan
Prior art keywords
composition according
combination
formula
tumor
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513700A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/001342 external-priority patent/WO2020115556A1/en
Publication of JP2022513700A publication Critical patent/JP2022513700A/ja
Publication of JP2022513700A5 publication Critical patent/JP2022513700A5/ja
Pending legal-status Critical Current

Links

JP2021531492A 2018-12-03 2019-12-03 放射性免疫複合体とチェックポイント阻害剤の併用療法 Pending JP2022513700A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862774847P 2018-12-03 2018-12-03
US62/774,847 2018-12-03
PCT/IB2019/001342 WO2020115556A1 (en) 2018-12-03 2019-12-03 Radioimmunoconjugates and checkpoint inhibitor combination therapy

Publications (2)

Publication Number Publication Date
JP2022513700A JP2022513700A (ja) 2022-02-09
JP2022513700A5 true JP2022513700A5 (cg-RX-API-DMAC7.html) 2023-10-25

Family

ID=70973593

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021531492A Pending JP2022513700A (ja) 2018-12-03 2019-12-03 放射性免疫複合体とチェックポイント阻害剤の併用療法
JP2021531486A Pending JP2022511471A (ja) 2018-12-03 2019-12-03 放射性免疫複合体とdnaの損傷および修復阻害剤の併用療法
JP2024193520A Pending JP2025013486A (ja) 2018-12-03 2024-11-05 放射性免疫複合体とdnaの損傷および修復阻害剤の併用療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021531486A Pending JP2022511471A (ja) 2018-12-03 2019-12-03 放射性免疫複合体とdnaの損傷および修復阻害剤の併用療法
JP2024193520A Pending JP2025013486A (ja) 2018-12-03 2024-11-05 放射性免疫複合体とdnaの損傷および修復阻害剤の併用療法

Country Status (18)

Country Link
US (5) US11446401B2 (cg-RX-API-DMAC7.html)
EP (2) EP3890790A4 (cg-RX-API-DMAC7.html)
JP (3) JP2022513700A (cg-RX-API-DMAC7.html)
KR (2) KR20210099073A (cg-RX-API-DMAC7.html)
CN (4) CN117482261A (cg-RX-API-DMAC7.html)
AU (2) AU2019394888A1 (cg-RX-API-DMAC7.html)
BR (2) BR112021010670A2 (cg-RX-API-DMAC7.html)
CA (2) CA3119917A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021001433A1 (cg-RX-API-DMAC7.html)
EA (2) EA202191557A1 (cg-RX-API-DMAC7.html)
IL (2) IL283598A (cg-RX-API-DMAC7.html)
MA (2) MA54399A (cg-RX-API-DMAC7.html)
MX (2) MX2021006408A (cg-RX-API-DMAC7.html)
PE (2) PE20211961A1 (cg-RX-API-DMAC7.html)
PH (2) PH12021551237A1 (cg-RX-API-DMAC7.html)
SG (2) SG11202105112RA (cg-RX-API-DMAC7.html)
WO (2) WO2020115556A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103429B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3125197A1 (en) * 2019-01-04 2020-07-09 Actinium Pharmaceuticals, Inc. Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
ES3075769T3 (en) 2019-05-10 2026-08-07 Janssen Biotech Inc Macrocyclic chelators and methods of use thereof
TW202131946A (zh) * 2020-01-10 2021-09-01 加拿大商融合製藥公司 持續性免疫療法
WO2021207086A1 (en) * 2020-04-06 2021-10-14 Fusion Pharmaceuticals Inc. Tem-1-targeted radioimmunoconjugates and uses thereof
CA3195512A1 (en) 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
WO2022087023A1 (en) * 2020-10-19 2022-04-28 Baruch S. Blumberg Institute Methods and kits for diagnosing and treating cancers
WO2022169634A1 (en) * 2021-02-02 2022-08-11 Unm Rainforest Innovations Combination therapy for the treatment of cancer
JP2024521418A (ja) * 2021-06-11 2024-05-31 フュージョン ファーマシューティカルズ インコーポレイテッド 放射性免疫複合体とチェックポイント阻害剤併用療法
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
JP2024531151A (ja) 2021-08-10 2024-08-29 ビリジアン セラピューティクス, インコーポレイテッド 甲状腺眼疾患の処置のための組成物、用量および方法
KR20240049818A (ko) * 2021-08-17 2024-04-17 테릭스 파마슈티컬스 (이노베이션스) 피티와이 엘티디 병용 방사선요법
US20250339571A1 (en) * 2021-08-27 2025-11-06 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer
WO2023049985A1 (en) * 2021-09-29 2023-04-06 National Research Council Of Canada Egfrviii-targeted compounds and uses thereof
AU2022379928A1 (en) * 2021-11-02 2024-05-09 Fusion Pharmaceuticals Inc. Methods of treating cancer
JP2025503215A (ja) * 2022-01-28 2025-01-30 フュージョン ファーマシューティカルズ インコーポレイテッド Ntsr1標的化放射性医薬品およびdna損傷応答阻害剤併用療法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5053503A (en) * 1989-02-17 1991-10-01 Centocor Chelating agents
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US7736651B1 (en) * 2000-11-24 2010-06-15 Sloan-Kettering Institute For Cancer Research Alpha emitting constructs and uses thereof
CA2593212A1 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
JP2009532027A (ja) * 2006-03-28 2009-09-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗igf−1r抗体およびその使用
US9556272B2 (en) * 2009-11-11 2017-01-31 The Trustees Of The University Of Pennsylvania Anti-TEM1 antibodies and uses thereof
IN2012DN03354A (cg-RX-API-DMAC7.html) 2009-12-02 2015-10-23 Immunomedics Inc
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
KR20190072663A (ko) * 2014-04-25 2019-06-25 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
EP3280439A1 (en) * 2015-04-07 2018-02-14 INSERM - Institut National de la Santé et de la Recherche Médicale Anti-pd-l1 immunotoxin for use in therapy
US11149087B2 (en) * 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
AU2016252038B2 (en) * 2015-04-20 2021-08-12 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
US20180169230A1 (en) * 2015-05-29 2018-06-21 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
JP7012645B2 (ja) * 2016-01-11 2022-01-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラタンパク質および免疫治療の方法
EP3202788A1 (en) 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialin-binding antibody
TWI822521B (zh) * 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
US11633506B2 (en) * 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
WO2018031507A1 (en) 2016-08-09 2018-02-15 Angimmune, Llc Treatment of cancer using a combination of immunomodulation and check point inhibitors
ES3071660T3 (en) * 2016-08-24 2026-06-24 Scinopharm Taiwan Ltd Processes for preparing olaparib
CA3035262A1 (en) * 2016-09-16 2018-03-22 Tina Christine Lavranos Antibody and checkpoint inhibitor combination therapy
JPWO2018110515A1 (ja) * 2016-12-12 2019-10-24 第一三共株式会社 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
WO2018153975A1 (en) * 2017-02-24 2018-08-30 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
AU2018261888B2 (en) * 2017-05-05 2022-06-30 Centre For Probe Development And Commercialization Pharmacokinetic enhancements of bifunctional chelates and uses thereof
US10093741B1 (en) * 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
EP3681541A4 (en) * 2017-09-13 2021-05-26 Radimmune Therapeutics, Inc. MELANINE ANTIBODIES AND USES THEREOF
CN111372613A (zh) * 2017-11-22 2020-07-03 诺帝克纳诺维科特公司 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤
WO2020169537A1 (en) * 2019-02-21 2020-08-27 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates

Similar Documents

Publication Publication Date Title
Bidkar et al. Actinium-225 targeted alpha particle therapy for prostate cancer
US20240335572A1 (en) Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
JP2020518674A5 (cg-RX-API-DMAC7.html)
Novak-Hofer et al. Copper-67 as a therapeutic nuclide for radioimmunotherapy
JP2022511471A5 (cg-RX-API-DMAC7.html)
EP2914302B1 (en) Radiolabelled antibody and uses thereof
RU2019139434A (ru) Моноклональные антитела против igf-1r и их применение
PL216208B1 (pl) Zastosowanie kompozycji leczniczej zawierającej niesprzężone i sprzężone przeciwciała w immunoterapii nowotworów złośliwych i choroby autoimmunizacyjnej
JP2020507571A (ja) 免疫petイメージングのための放射標識抗lag3抗体
JP2020518673A5 (cg-RX-API-DMAC7.html)
EP1763372B1 (en) Radionuclides for medical use
JP7836270B2 (ja) 抗dota/抗腫瘍抗原二重特異性抗体による事前標的化放射免疫治療のためのdota-ハプテン組成物
JP2025039567A (ja) 二重特異性結合因子およびその使用
CN114555132A (zh) 放射性金属标记抗体的制造方法
JP2024091815A (ja) 疾患または状態を処置するための組成物およびそれらの使用
US20220378956A1 (en) Trivalent Radioisotope Bio-Targeted Radiopharmaceutical, Methods Of Preparation And Use
TW201627286A (zh) 放射性醫藥複合物
Song et al. Bismuth-213 radioimmunotherapy with C595 anti–MUC1 monoclonal antibody in an ovarian cancer ascites model
CN117836011A (zh) 将生物制剂与多种螯合剂组合的方法和材料
CN113795511B (zh) 抗pd-l1双抗体及其用途
WO2026037323A1 (zh) 放射性核素标记的靶向pd-l1小蛋白及其制备方法与应用
JP2024521418A5 (cg-RX-API-DMAC7.html)
KR20220125330A (ko) 지속 면역요법
JP2018168068A (ja) 抗ポドプラニン抗体及び抗体薬物複合体
Rousseau et al. Radiolabeled antibodies for cancer radioimmunotherapy